Clinical high-risk criteria of psychosis in 8–17-year-old community subjects and inpatients not suspected of developing psychosis

Table 3 Frequency of clinical high-risk criteria in the two groups (n = 539)

	Inpatients (n = 306)	Community subjects (n = 233)	χ² test; Cramer’s V
BIPS syndrome: n (%)	0	0	--
APS syndrome: n (%)	7 (2.3)	5 (2.1)	χ² (1) = 0.012; P = 0.912, V = 0.005
Genetic risk and functional decline syndrome: n (%)	2 (0.6)	0	χ² (1) = 1.529; Pexact = 0.508, V = 0.053
COGDIS: n (%)	10 (3.3)	4 (1.7)	χ² (1) = 1.258; P = 0.262, V = 0.048
COPER: n (%)	21 (6.9)	10 (4.3)	χ² (1) = 1.613; P = 0.204, V = 0.055
Any 1 of 5 CHR criteria: n (%)	29 (9.5)	17 (7.3)	χ² (1) = 0.806; P = 0.369, V = 0.039
Any 1 of 3 EPA criteria: n (%)	15 (4.9)	9 (3.9)	χ² (1) = 0.336; P = 0.562, V = 0.025
No CHR criterion: n (%)	277 (90.5)	216 (92.7)	χ² (7) = 5.676; P = 0.578, V = 0.103
Only genetic risk and functional decline: n (%)	2 (0.7)	0
Only COPER: n (%)	12 (3.9)	8 (3.4)
Only COGDIS: n (%)	2 (0.7)	2 (0.9)
COPER and COGDIS: n (%)	6 (2.0)	2 (0.9)
Only APS: n (%)	4 (1.3)	5 (2.1)
APS and COPER: n (%)	1 (0.3)	0
APS, COPER and COGDIS: n (%)	2 (0.7)	0

BIPS: Brief intermittent psychotic symptoms; APS: Attenuated psychotic symptoms; COGDIS: Cognitive Disturbances; COPER: Cognitive–Perceptive Basic Symptoms; EPA: European Psychiatric Association. V: Cramer’s V: 0.1 = weak effect; 0.3 = moderate effect; 0.5 = strong effect.